Pramlintide vs Liraglutide
A shot added to mealtime insulin in diabetes. Controlled trials show a small drop in blood sugar and weight, with more nausea and low blood sugar. It is a daily injection for type 2 diabetes and for weight loss. Large trials of 9,340 and 3,731 people showed fewer heart problems and about 8% weight loss.
Both sit at grade A: strong human evidence. Both are FDA approved.
Evidence
AStrong human evidence
AStrong human evidence
Human studies cited
Animal or cell studies cited
Why the grade
Approval rested on randomized, placebo-controlled trials in type 1 and type 2 diabetes lasting up to a year; the label summarizes six placebo-controlled trials (four in type 1 and two in type 2 diabetes), the largest with 480 type 1 patients, in which pramlintide lowered HbA1c by about 0.25 to 0.34 percentage points more than placebo and reduced weight. The effect is real but small, and the drug has largely been displaced by GLP-1 agonists.
Both uses rest on large randomized placebo-controlled trials: LEADER (9,340 patients with type 2 diabetes, cardiovascular outcomes) and the SCALE obesity trial (3,731 adults, 56 weeks of weight loss). Multiple other phase 3 trials sit behind the labels. What the citations do not cover is how liraglutide compares with the newer weekly GLP-1 drugs, which outperform it on weight.
FDA
FDA approved
Pramlintide is FDA-approved as Symlin (approved March 2005) for adults with type 1 or type 2 diabetes who use mealtime insulin and have not reached their glucose targets. The label carries a boxed warning about severe hypoglycemia, which is why insulin doses are reduced when it is started.
FDA approved
Approved. Liraglutide is sold as Victoza (approved 2010) for type 2 diabetes in adults and children aged 10 and older and to reduce major cardiovascular events in adults with type 2 diabetes and heart disease, and as Saxenda (approved 2014) for chronic weight management in adults and adolescents aged 12 and older. Generic liraglutide for both indications has been approved since December 2024 and August 2025.
Sold for
Pramlintide is the only approved amylin drug, used as an add-on to mealtime insulin to blunt after-meal glucose spikes and help with weight.
Liraglutide was the first daily GLP-1 drug to be approved for weight loss and is now marketed as the cheaper generic alternative to semaglutide for people who want a GLP-1 but cannot get or afford the newer ones.
Studies say
Randomized trials show pramlintide modestly lowers HbA1c and body weight when added to insulin, at the cost of nausea and a higher risk of insulin-related hypoglycemia, which supports its narrow approved use.
Trials in nearly 10,000 diabetic patients and 3,700 adults with obesity showed fewer heart events and about 8 percent body weight loss respectively, which earns an A for both approved uses.
Class
Amylin analog
GLP-1 receptor agonist
Route
Injection
Injection